{"analyses":[{"ciLowerLimit":"75.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"82.85","groupDescription":"Of the 498 eligible patients, 492 were successfully evaluated with day 46 MRD measurement.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Binomial proportion","paramValue":"79.27","statisticalMethod":"Binomial proportion"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"390"}]}],"title":"Negative <0.01%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"102"}]}],"title":"Positive >= 0.01%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"492"}],"units":"Participants"}],"description":"Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (\\>=0.01%).","groups":[{"description":"Total therapy applies to all eligible patients.","id":"OG000","title":"Total Therapy"}],"paramType":"NUMBER","populationDescription":"Patients who completed induction and had successful MRD studies on day 46.","reportingStatus":"POSTED","timeFrame":"End of Induction (Day 46 MRD measurement)","title":"Minimal Residual Disease (MRD)","type":"SECONDARY","unitOfMeasure":"participants"}